Cargando…
Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure
Recent scientific publications have reported cases of patients who complained from a variety of symptoms after they received a gadolinium-based contrast agent (GBCA). The aim of this study was to appreciate the importance of these clinical manifestations in the overall population by assessing the we...
Autores principales: | Shahid, Imran, Joseph, Alvin, Lancelot, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444285/ https://www.ncbi.nlm.nih.gov/pubmed/35471204 http://dx.doi.org/10.1097/RLI.0000000000000880 |
Ejemplares similares
-
Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain
por: Anderhalten, Lina, et al.
Publicado: (2022) -
Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent
por: Lohrke, Jessica, et al.
Publicado: (2022) -
Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals
por: Young, Laura K., et al.
Publicado: (2018) -
Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021) -
Feasibility and accuracy of dual-layer spectral detector computed tomography for quantification of gadolinium: a phantom study
por: van Hamersvelt, Robbert W., et al.
Publicado: (2017)